More evidence links breast cancer, hormone therapy

Key points
- Hormone replacement therapy increases the risk of breast cancer, especially among women receiving a combination of estrogen and progestin, a major British study found.
- The report, published in this week's edition of The Lancet, a British medical journal, concluded that women now receiving hormone replacement therapy had a 22 percent higher risk of death from breast cancer compared to women who were not receiving therapy.
- However, a U.S. medical specialist who was not involved in the British study said it did not settle the question of whether estrogen by itself posed a significantly higher risk of cancer.
- The Lancet report was based on the "Million Woman Study" which surveyed 1,084,110 women in the United Kingdom aged 50 to 64.
Hormone replacement therapy increases the risk of breast cancer, especially among women receiving a combination of estrogen and progestin, a major British study found.
The report, published in this week's edition of The Lancet, a British medical journal, concluded that women now receiving hormone replacement therapy had a 22 percent higher risk of death from breast cancer compared to women who were not receiving therapy.
However, a U.S. medical specialist who was not involved in the British study said it did not settle the question of whether estrogen by itself posed a significantly higher risk of cancer.
The Lancet report was based on the "Million Woman Study" which surveyed 1,084,110 women in the United Kingdom aged 50 to 64. They were recruited between 1996 and 2001, and tracked for cancer incidence and death.
Professor Valerie Beral, director of the Cancer Research UK Epidemiology Unit and lead author of the study, said there was "overwhelming evidence" that the combination therapy was associated with a greater cancer risk.
Among 1,000 postmenopausal women who do not use hormone replacement therapy, or HRT, there will be around 20 breast cancer cases among women between the ages of 50 and 60, Beral said.
In every 1,000 women who begin 10 years of HRT at the age of 50, there will be five extra cases among estrogen-only users, and 19 among estrogen-progestin combination users, she said.
"The evidence is now compelling that estrogen plus progestin is more deleterious to the breast than estrogen alone," said Dr. JoAnn Manson of the Harvard University Medical School.
"However, there continues to be controversy about whether unopposed estrogen increases the risk of breast cancer," said Manson, who was not involved in the British study.
Manson said the Women's Health Initiative, a U.S. government-sponsored study of 16,608 postmenopausal women ages 50 to 79, "will provide conclusive answers to this question in the next two years."
Content provided by ArmMed Media
Revision date: 12 December 2007
Last revised by Amalia K. Gagarina, M.S., R.D.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsLong-Term Use of Estrogen Hormone Therapy Linked to Higher Risk for Breast Cancer
In a landmark study, researchers have linked the long-term use of estrogen plus progesterone and estrogen-only hormone therapy with a higher risk for developing breast cancer. “It’s already been confirmed that patients…
2 April 2012
NewsStopping hormones might help breast cancer to regress
As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology,…
29 February 2012
NewsDoes hormone replacement therapy cause breast cancer
Based principally on findings in three studies, the collaborative reanalysis (CR), the Women’s Health Initiative (WHI) and the Million Women Study (MWS), it is claimed that hormone replacement therapy (HRT) with estrogen…
16 February 2012


